FDA Rejects Sobi’s Gout Drug Over Manufacturing Issues, Sparing Amgen Blockbuster
The FDA has rejected Sobi’s application for its gout treatment, a decision primarily attributed to manufacturing issues. This setback halts Sobi’s efforts to compete with Amgen’s established blockbuster, Krystexxa, which has dominated the market since its launch. This rejection underscores the critical importance of robust manufacturing processes in drug approval, particularly in a highly regulated…
